アピゲニンの産生方法
    2.
    发明专利
    アピゲニンの産生方法 审中-公开
    生产APIGININ的方法

    公开(公告)号:JP2014201529A

    公开(公告)日:2014-10-27

    申请号:JP2013077288

    申请日:2013-04-02

    摘要: 【課題】植物体を焙煎することで配糖体から糖を分離してアグリコン、特に馬鞭草中におけるエストロゲン様生理活性物質であるアピゲニンを増加させる方法を提供する。【解決手段】例えば馬鞭草のようにアピゲニンの配糖体及び/又はアピゲニンの類縁物質を含む植物体を焙煎して、植物体中に含まれるエストロゲン様生理活性物質量を増やす。得られた焙煎植物体は、いわゆる茶葉として利用される。また、エストロゲン様生理活性物質であるアピゲニンの抽出原料として利用される。【選択図】図3

    摘要翻译: 要解决的问题:提供一种通过焙烧植物体来分离葡萄糖苷中的糖分,从而通过将植物体中的糖分离出葡萄糖苷来增加苷元,特别是马鞭草中的雌激素生物活性物质的芹菜素。解决方案:植物体,例如包括芹菜素的葡萄糖苷和 /或芹菜素类似物质如马鞭草等,以增加包括在植物体内的雌激素生物活性物质的量。 所获得的烤制植物体被用作所谓的茶叶。 而且,作为雌激素生物活性物质的芹菜素的提取原料也被利用。

    Process for preparing polymethoxyflavones
    5.
    发明专利
    Process for preparing polymethoxyflavones 有权
    制备聚甲基纤维素的方法

    公开(公告)号:JP2010037317A

    公开(公告)日:2010-02-18

    申请号:JP2008205527

    申请日:2008-08-08

    摘要: PROBLEM TO BE SOLVED: To provide a process for preparing inexpensive and safe polymethoxyflavones usable for foods having adaptability to various medicines that can separate a large amount of polymethoxyflavones all at once from other components in citrus peel oil, and a method for using them. SOLUTION: The process for preparing polymethoxyflavones by which the polymethoxyflavones are separated as a distillate by distilling the residue in a thin-film vacuum distillation apparatus obtained by removing volatile components from the citrus peel oil by distillation is provided. A composition containing the polymethoxyflavones prepared by the method is also provided. COPYRIGHT: (C)2010,JPO&INPIT

    摘要翻译: 解决问题的方法:提供一种制备廉价且安全的多甲氧基黄酮的方法,所述多甲氧基黄酮可用于具有适合各种药物的食品,所述各种药物可以与柑橘类皮肤油中的其它成分同时分离大量的聚甲氧基黄酮,以及使用 他们。 提供了制备聚甲氧基黄酮的方法,其中通过在通过蒸馏从柑橘皮油中除去挥发性组分而获得的薄膜真空蒸馏装置中蒸馏残留物,将聚甲氧基黄酮作为馏出物分离。 还提供了含有通过该方法制备的聚甲氧基黄酮的组合物。 版权所有(C)2010,JPO&INPIT

    Mitf gene expression promotion substance
    6.
    发明专利
    Mitf gene expression promotion substance 审中-公开
    MITF基因表达促进物质

    公开(公告)号:JP2006028143A

    公开(公告)日:2006-02-02

    申请号:JP2004213569

    申请日:2004-07-21

    摘要: PROBLEM TO BE SOLVED: To obtain a melanocyte activity promtion agent that is safe and has high effectiveness and provide an anti-hair-whitening agent by using the same. SOLUTION: The MITF gene (microphtalmia-assoeiated transcription factor) expression promoting substance includes one or two or more kinds of compounds selected from the group consisting of chalcones, fravanones, and isomuhulones that are trace constituents in hop. For example, xanthofumol in chalcones, isoxanthofumol in fravanones and isomufron in isomufurons, and the like, have shown very high MITF gene expression promotion effect in a very thin concentration of 1 × 10 -7 mass%. COPYRIGHT: (C)2006,JPO&NCIPI

    摘要翻译: 要解决的问题:获得安全和有效性的黑素细胞活性促进剂,并通过使用该黑素细胞活性促进剂提供抗发美白剂。 解决方案:MITF基因(微呼吸综合转录因子)表达促进物质包括选自以下的一种或两种以上的化合物:作为跳跃的痕量成分的查尔酮,fravanones和异香豆素。 例如,沙酮中的黄曲霉醇,弗拉福酮中的异黄酮醇和异黄酮中的异麦芽糖等已经以非常薄的1×10 -6质量%的浓度显示出非常高的MITF基因表达促进作用。 版权所有(C)2006,JPO&NCIPI

    NOVEL FLAVONE COMPOUND
    9.
    发明专利

    公开(公告)号:JPS63227584A

    公开(公告)日:1988-09-21

    申请号:JP6130487

    申请日:1987-03-18

    摘要: NEW MATERIAL:A compound shown by the formula. USE:Useful as an antiasthmatic agent and antiallergic drug having inhibitory action on leukotriene production and histamine liberation. PREPARATION:For example, dried Verbascum thapsus is extracted with an organic solvent (e.g. n-hexane) having relatively low polarity for 24hr under reflux, the solvent is removed from the extracted solution to give powder, which is subjected to column chromatography. Impurities are separated to give a flavonol fraction, which is subjected to Sephadex and purified to give the aimed flavonol.

    PHARMACOLOGICALLY ACTIVE KETONE COMPOUND

    公开(公告)号:JPS60109523A

    公开(公告)日:1985-06-15

    申请号:JP22381984

    申请日:1984-10-24

    申请人: WELLCOME FOUND

    摘要: Use of compounds of formulae (la) and (lb)to provide a more effective delivery of oxygen to the tissues of a mammalian, including human, recipient.In vivo applications include the relief or amelioration of conditions wherein there is tissue hypoxia; in vitro the compounds are of use in the storage of mammalian, including human, red blood cells to maintain their oxygen-delivery capacity and prolong their useful storage iife.Also provided is a sterile, sealed vessel containing an anticoagulant, a non-toxic amount of a compound of formula (la) or (lb) and optionally mammalian, in particular human, red blood cells.